Skip to main content

Rabbit Recombinant Monoclonal PD-L1 antibody - conjugated to FITC. Suitable for Flow Cyt, ICC/IF and reacts with Human samples. Cited in 1 publication.

Be the first to review this product! Submit a review

Images

Key facts

Isotype

IgG

Host species

Rabbit

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Storage buffer

Preservative: 0.02% Sodium azide
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA

Form

Liquid

Clonality

Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
Flow CytICC/IF
Human
Tested
Tested
Chinese hamster
Not recommended
Not recommended

Tested
Tested

Species

Human

Dilution info

1/500

Notes

-

Not recommended
Not recommended

Species

Chinese hamster

Dilution info

-

Notes

-

Tested
Tested

Species

Human

Dilution info

1/100

Notes

This product gave a positive signal in CHO-PDL1 cells fixed with 4% formaldehyde (10 min)

Not recommended
Not recommended

Species

Chinese hamster

Dilution info

-

Notes

-

Target data

Function

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

Alternative names

Recommended products

  1. Loading...
  2. Loading...
  3. Loading...
  4. Loading...

Rabbit Recombinant Monoclonal PD-L1 antibody - conjugated to FITC. Suitable for Flow Cyt, ICC/IF and reacts with Human samples. Cited in 1 publication.

Alternative names

Key facts

Isotype

IgG

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Form

Liquid

Clonality

Monoclonal

Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number

28-8

Purification technique

Affinity purification Protein A

Concentration
Loading...

Storage

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle, Store in the dark

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Activity summary

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

Associated diseases and disorders

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

  • Flow Cytometry - FITC Anti-PD-L1 antibody [28-8] (ab224027), expandable thumbnail

    Flow Cytometry - FITC Anti-PD-L1 antibody [28-8] (ab224027)

    Overlay histogram showing CHO-S (blue line) and CHO-PD-L1 transfected (red line) cells stained with ab224027.

    The cells were incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab224027, 1/500 dilution) for 30 min at 22°C.

    Acquisition of >5,000 events were collected using a 20 mW solid-state laser (488nm) and 530/30 bandpass filter.

  • Immunocytochemistry/ Immunofluorescence - FITC Anti-PD-L1 antibody [28-8] (ab224027), expandable thumbnail

    Immunocytochemistry/ Immunofluorescence - FITC Anti-PD-L1 antibody [28-8] (ab224027)

    ab224027 staining PDL1 in CHO-PDL1 cells. The lower panels demonstrate that ab224027 does not cross react with un-transfected CHO-S cells.

    The cells were fixed with 4% formaldehyde (10 min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab224027 at 1/100 dilution (shown in green) and ab195889, Mouse monoclonal to alpha Tubulin (Alexa Fluor® 594), at 1/250 dilution (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).

    Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

There was a problem

We can’t download that datasheet. Please try again. If you need help, contact our Customer Services team at technical@abcam.com